Insider · CIK 0001570392

TOMSICEK MICHAEL JOHN

Reports to the SEC for 5 companies · WATERTOWN, MA

sec.gov

Transactions

Companies

Filings

CIK

0001570392

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-17	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20.3K sh	—	—	20,275
2026-06-10	MISTMilestone Pharmaceuticals Inc. · Stock Option (right to buy)A Award	Director	AAward	+77K sh	—	—	77,000
2026-05-18	ACRVAcrivon Therapeutics, Inc.A Award	Director	AAward	+9,366 sh	—	—	9,366
2025-06-13	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20.3K sh	—	—	20,275
2025-06-10	MISTMilestone Pharmaceuticals Inc. · Stock Option (right to buy)A Award	Director	AAward	+40K sh	—	—	40,000
2024-08-28	MISTMilestone Pharmaceuticals Inc. · Stock Option (right to buy)A Award	Director	AAward	+40K sh	—	—	40,000
2024-06-20	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20.3K sh	—	—	20,275
2023-06-07	MISTMilestone Pharmaceuticals Inc. · Stock Option (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2022-11-14	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+35.2K sh	—	—	35,235
2022-10-19	MISTMilestone Pharmaceuticals Inc.P Purchase	Director	PPurchase	+15K sh	$5.32	+$79.8K	15,000
2022-07-05	MISTMilestone Pharmaceuticals Inc. · Stock Option (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2021-08-06	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+25K sh	$17.75	+$444K	26,891
2021-08-06	CRSPCRISPR Therapeutics AGS Sale	Chief Financial Officer	SSale	−19K sh	$138.22	−$2.63M	7,880
2021-08-06	CRSPCRISPR Therapeutics AGS Sale	Chief Financial Officer	SSale	−5,989 sh	$139.46	−$835K	1,891
2021-06-14	MISTMilestone Pharmaceuticals Inc. · Stock Option (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2021-03-11	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−25K sh	—	—	131,000
2021-03-11	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+25.4K sh	—	—	25,360
2021-03-11	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+9,000 sh	—	—	9,000
2021-03-10	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,833 sh	—	—	3,243
2021-03-10	CRSPCRISPR Therapeutics AGF Tax Payment	Chief Financial Officer	FTax Payment	−1,352 sh	$124.15	−$168K	1,891
2020-10-05	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+11.7K sh	—	—	11,666
2020-09-01	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+12K sh	$17.75	+$213K	12,410
2020-09-01	CRSPCRISPR Therapeutics AGS Sale	Chief Financial Officer	SSale	−2,800 sh	$91.39	−$256K	9,610
2020-09-01	CRSPCRISPR Therapeutics AGS Sale	Chief Financial Officer	SSale	−6,400 sh	$92.23	−$590K	3,210
2020-09-01	CRSPCRISPR Therapeutics AGS Sale	Chief Financial Officer	SSale	−2,800 sh	$93.18	−$261K	410
2020-09-01	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−12K sh	—	—	156,000
2020-08-03	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+12K sh	$17.75	+$213K	12,410
2020-08-03	CRSPCRISPR Therapeutics AGS Sale	Chief Financial Officer	SSale	−6,552 sh	$86.25	−$565K	5,858
2020-08-03	CRSPCRISPR Therapeutics AGS Sale	Chief Financial Officer	SSale	−5,448 sh	$87.33	−$476K	410
2020-06-05	MISTMilestone Pharmaceuticals Inc. · Stock Option (right to buy)A Award	Director	AAward	+15K sh	—	—	15,000
2020-03-10	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+35K sh	—	—	35,000
2020-03-10	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+8,500 sh	—	—	8,500
2019-12-03	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+20K sh	—	—	20,000
2019-03-05	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+75K sh	—	—	75,000
2018-06-15	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+20.8K sh	—	—	20,760
2018-03-07	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+25K sh	—	—	25,000
2017-11-13	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−12K sh	—	—	168,000
2017-11-13	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+180K sh	—	—	180,000
2017-07-15	ABIOMED INCF Tax Payment	Vice President, CFO	FTax Payment	−3,925 sh	$145.07	−$569K	27,081
2017-05-24	ABIOMED INCF Tax Payment	Vice President, CFO	FTax Payment	−1,567 sh	$134.74	−$211K	34,931
2017-05-15	ABIOMED INCA Award	Vice President, CFO	AAward	+8,198 sh	—	—	34,998
2017-05-15	ABIOMED INCA Award	Vice President, CFO	AAward	+1,500 sh	—	—	36,498
2017-05-15	ABIOMED INCStock option (right to buy)A Award	Vice President, CFO	AAward	+6,000 sh	—	—	6,000
2016-05-24	ABIOMED INCA Award	Vice President, CFO	AAward	+1,800 sh	—	—	26,800
2016-05-24	ABIOMED INCStock option (right to buy)A Award	Vice President, CFO	AAward	+5,000 sh	—	—	5,000
2015-07-15	ABIOMED INCA Award	Vice President, CFO	AAward	+25K sh	—	—	25,000
2015-07-15	ABIOMED INCStock option (right to buy)A Award	Vice President, CFO	AAward	+25K sh	—	—	25,000
2015-07-15	ABIOMED INCStock option (right to buy)A Award	Vice President, CFO	AAward	+25K sh	—	—	25,000
2015-01-21	CUBIST PHARMACEUTICALS INCJ Other	SVP & Chief Financial Officer	JOther	−14.8K sh	$102.00	−$1.51M	0
2015-01-21	CUBIST PHARMACEUTICALS INCJ Other	SVP & Chief Financial Officer	JOther	−1,199 sh	$102.00	−$122K	0

Recent filings

Accepted (ET)
Jun 224
TOMSICEK MICHAEL JOHN0000905148-26-003042
SEC(opens sec.gov)
Jun 124
TOMSICEK MICHAEL JOHN0001570392-26-000003
SEC(opens sec.gov)
May 204
TOMSICEK MICHAEL JOHN0000905148-26-002563
SEC(opens sec.gov)
Jun 174
TOMSICEK MICHAEL JOHN0000905148-25-002174
SEC(opens sec.gov)
Jun 124
TOMSICEK MICHAEL JOHN0001415889-25-016934
SEC(opens sec.gov)
Aug 294
TOMSICEK MICHAEL JOHN0001415889-24-022535
SEC(opens sec.gov)
Jun 244
TOMSICEK MICHAEL JOHN0000905148-24-001777
SEC(opens sec.gov)
Jun 94
TOMSICEK MICHAEL JOHN0001209191-23-035843
SEC(opens sec.gov)
Nov 164
TOMSICEK MICHAEL JOHN0001209191-22-057401
SEC(opens sec.gov)
Oct 214
TOMSICEK MICHAEL JOHN0001209191-22-054325
SEC(opens sec.gov)
Aug 114
TOMSICEK MICHAEL JOHN0001209191-22-045474
SEC(opens sec.gov)
Aug 104
TOMSICEK MICHAEL JOHN0001209191-21-050719
SEC(opens sec.gov)
Jul 294
TOMSICEK MICHAEL JOHN0001209191-21-048573
SEC(opens sec.gov)
Mar 124
TOMSICEK MICHAEL JOHN0001209191-21-020263
SEC(opens sec.gov)

Companies

Address

C/O ACRIVON THERAPEUTICS, INC. 480 ARSENAL WAY, SUITE 100

WATERTOWN, MA, 02472